The results obtained in our study are consistent with those obtained in the pivotal trial.
PFS seem to be better when nab-paclitaxel is used as a first line and in patients with ECOG 0, but the differences aren’t statistically significant. A bigger sample would be needed to confirm all results.
The AE described are similar to those published in the literature.